| 期 |
栏目 |
标题 |
文件 |
| 编号 14 (2012) |
Articles |
Arterial'naya gipertenziya i kognitivnye narusheniya: vozmozhnosti korrektsii |
|
| 编号 14 (2012) |
Articles |
Variabel'nost' arterial'nogo davleniya -novaya mishen' dlya profilaktiki insul'ta |
|
| 编号 13 (2013) |
Articles |
Vliyanie amlodipina na kognitivnye funktsii u pozhilykh bol'nykh arterial'noy gipertoniey |
|
| 编号 6 (2014) |
Articles |
Dislipidemiya u patsienta s arterial'noy gipertenziey: kombinirovannaya terapiya gipolipidemicheskimi i antigipertenzivnymi lekarstvennymi sredstvami |
|
| 编号 18 (2014) |
Articles |
Vozmozhnosti korrektsii dislipidemii u patsientov s arterial'noy gipertenziey |
|
| 编号 9 (2017) |
Articles |
ALGORITHM OF THE SELECTION OF ANTIHYPERTENSIVE THERAPY AGAINST THE INVOLVEMENT OF HEART AS A TARGET ORGAN IN ARTERIAL HYPERTENSION |
|
| 编号 15 (2017) |
Articles |
Possibilities of amlodipine/lisinopril fixed-dose combination in real clinical practice |
|
| 编号 15 (2017) |
Articles |
Cerebroprotective effects of fixed-dose combination of perindopril arginine/ indapamide |
|
| 卷 26, 编号 4 (2019) |
Articles |
Potential drug interactions of oral hypoglycemic drugs that increase the risk of hypoglycemia |
|
| 卷 26, 编号 9 (2019) |
Articles |
Drug-induced pirouette-type tachycardia |
|
| 卷 26, 编号 9 (2019) |
Articles |
Drug-induced nightmares |
|
| 卷 26, 编号 14 (2019) |
Articles |
Hypoglycemic drugs and drug-induced heart failure |
|
| 卷 26, 编号 14 (2019) |
Articles |
Drug-induced hyperthyroidism |
|
| 卷 27, 编号 2 (2020) |
Articles |
Medicines associated with the development of drug-induced constipation |
|
| 卷 27, 编号 4 (2020) |
Articles |
Individual drugs associated with overweight inducing |
|
| 卷 27, 编号 4 (2020) |
Articles |
Medicines associated with the development of osteoporosis |
|
| 卷 27, 编号 3 (2020) |
Articles |
Approaches to choosing a direct oral anticoagulant in the treatment of polymorbid patients with atrial fibrillation |
|
| 卷 27, 编号 3 (2020) |
Articles |
Drug-induced hypothyroidism |
|
| 卷 27, 编号 3 (2020) |
Articles |
The benefits of fixed combinations for the treatment of arterial hypertension in women with menopausal disorders: focus on Gipotef |
|
| 卷 27, 编号 5 (2020) |
Articles |
Drug-induced diseases: epidemiology and urgency of the problem |
|
| 卷 27, 编号 6 (2020) |
Articles |
Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance |
|
| 卷 27, 编号 13 (2020) |
Articles |
The role of the disturbances in the intestinal barrier structure in relation to cardiovascular diseases pathogenesis and rebamipid potential in their correction |
|
| 卷 27, 编号 13 (2020) |
Articles |
Drug-induced liver injury with cholestasis. Part 1: focus on drugs for the treatment of cardiovascular diseases and hypoglycemic drugs |
|
| 卷 27, 编号 14 (2020) |
Articles |
Drug-induced liver injury with cholestasis. Part 2: focus on antidiabetic drugs |
|
| 卷 28, 编号 2 (2021) |
Articles |
Drug-induced autoimmune hepatitis |
|
| 卷 28, 编号 3 (2021) |
Articles |
Drug-induced atrial fibrillation/flutter associated with drugs affecting the central nervous system |
|
| 卷 28, 编号 3 (2021) |
Articles |
The relationship of cardiovascular disease with increased intestinal permeability: results from scientific and controlled clinical trials. Focus on the potential of rebamipide |
|
| 卷 28, 编号 3 (2021) |
Articles |
The choice of antianginal therapy for polymordib patients with coronary artery disease and type 2 diabetes mellitus: the benefits of trimetazidine |
|
| 卷 28, 编号 5 (2021) |
Articles |
Tobacco smoking as a risk factor for the development of drug-induced diseases |
|
| 卷 28, 编号 10 (2021) |
Articles |
Potential clinically significant drug interactions of drugs with green tea |
|
| 卷 28, 编号 11 (2021) |
Articles |
Risk factors of drug-induced diseases. Part 1. Classification, non-modified risk factors |
|
| 卷 28, 编号 11 (2021) |
Articles |
Medication errors as risk factor for drug-induced diseases |
|
| 卷 29, 编号 6 (2022) |
Articles |
Drug-induced kidney stone disease |
|
| 卷 29, 编号 6 (2022) |
Articles |
Drugs, the use of which is associated with the development of drug-induced kidney stone disease. Part 1 |
|
